Table 1.

Demographic and clinical variables of included participants with SSc (n=46), stratified by high versus low levels of emotional well-being (UCLA SCTC GIT 2.0 well-being subscale ≥0.50). IQR= interquartile range, SSRI/SNRI= selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitors, TCA= tricyclic antidepressant, RP= Raynaud’s phenomenon, GI= gastrointestinal.

	Low Emotional Distress [GIT Emotional Well- Being <0.50], (n=18)	High Emotional Distress [GIT Emotional Well-Being >0.50], (n=28)	p-value
Age, median (IQR)	55 (47, 61)	58 (52, 68)	0.07
Age at Symptom Onset, median (IQR)	48 (38, 52)	46 (32, 54)	0.94
Disease Duration	8.1 (5.4, 12.0)	13.0 (6.9, 22.4)	0.09
Sex (n, % female)	15 (83)	23 (82)	0.92
Race (n, % White)	4 (22)	4 (14)	0.49
Smoking Status (% yes)
Never	9 (50)	18 (64)	0.61
Former/Current	9 (50)	10 (36)
Limited Skin Type (n, %yes)	10 (56)	22 (81)	0.06
Current Medications (n, % yes)
Prednisone	1 (6)	2 (7)	0.85
Opioids	1 (6)	3 (11)	0.56
Reflux Med *	14 (78)	27 (96)	0.05
Methotrexate	1 (6)	3 (11)	0.54
Mycophenolate	5 (28)	7 (25)	0.83
SSRI/SNRI	4 (22)	10 (36)	0.33
TCA	1 (6)	1 (4)	0.75
Sleep-Aid	4 (22)	4 (14)	0.49
Benzodiazepine	3 (17)	6 (21)	0.69
Beta-Blocker	3 (17)	6 (21)	0.69
Medsger Severity Score (n, % yes)
RP (>2)	7 (39)	8 (29)	0.47
Lung (>2)	10 (56)	13 (46)	0.55
Heart (>1)	8 (44)	11 (39)	0.73
GI (>2)	9 (50)	19 (68)	0.23
Transit: Delayed Emptying
Esophageal	8 (47)	13 (62)	0.36
Gastric (Solid)	3 (18)	3 (13)	0.69
Small Bowel	2 (12)	2 (9)	0.75
Large Bowel	9 (53)	15 (68)	0.33
Arthralgias (%Yes)	6 (33)	15 (54)	0.15
Synovitis (%Yes)	0 (0)	3 (11)	0.15
Sicca (%Yes)	10 (56)	16 (57)	0.92
Antibody Positivity (n, %yes)
Scl-70	6 (33)	6 (21)	0.37
Ro52	5 (28)	6 (21)	0.62
Centromere (A/B)	6 (33)	18 (64)	0.04
RNA pol-III	3 (17)	1 (4)	0.12
PM-Scl (75/100)	6 (33)	2 (7)	0.02

^*Reflux medication defined as use of an antacid, proton pump inhibitor, or H2-blocker.